1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemER547Cat. No.: HY-10014CAS No.: 741713-40-6分式: CHFNOS分量: 441.45作靶點: CDK作通路: Cell Cycle/DNA Damage儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實驗 DMSO : 50 mg/mL (113.26 mM)H2O : 40% PEG300 5% Tween

2、-80 45% salineSolubility: 2.5 mg/mL (5.66 mM); Clear solution2. 請依序添加每種溶劑： 10% DMSO 90% corn oilSolubility: 2.5 mg/mL (5.66 mM); Clear solution1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemEBIOLOGICAL ACTIVITY物活性 R547是ATP競爭性CDK1，2，4抑制劑，Ki分別為2 nM，3 nM和1 nM。IC50 & Target Cdk1/cyclin B CDK4/cyclin D

3、CDK2/cyclinE2 nM (Ki) 1 nM (Ki) 3 nM (Ki)戶使本產(chǎn)品發(fā)表的科研獻 Science. 2017 Dec 1;358(6367). Cell Chem Biol. 2018 Feb 15;25(2):135-142.e5.See more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Chu XJ, DePinto W, Bartkovitz D, So SS, Vu BT, Packman K, Lukacs C, Ding Q, Jiang N, Wang K, Goelzer

4、P, Yin X, Smith MA, HigginsBX, Chen Y, Xiang Q, Moliterni J, Kaplan G, Graves B, Lovey A, Fotouhi N.Discovery of 4-Amino-2-(1-methanesulfonylpiperidin-42. Bays M, Rabasseda X, Prous JR.Gateways to clinical trials.Methods Find Exp Clin Pharmacol. 2007 Jul-Aug;29(6):427-37.3. Martin F, Thomson TM, Sew

5、er A, Drubin DA, Mathis C, Weisensee D, Pratt D, Hoeng J, Peitsch MC.Assessment of networkperturbation amplitudes by applying high-throughput data to causal biological networks.BMC Syst Biol. 2012 May 31;6:54.4. DePinto, Wanda et al In vitro and in vivo activity of R547: a potent and selective cycli

6、n-dependent kinase inhibitor currently in phase Iclinical trials Molecular Cancer Therapeutics (2006), 5(11), 2644-26585. Jones, Clifford D.; Andrews, David M. Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitorsBioorganic & Medicinal Chemistry Letters (2008), 18(24), 6486-6489McePdfHeightCaution: Product has not been fully validated for medical applications.For research use only.Tel: 4